Glyset R SC Injection
SC Injection
Enterprise Pharmaceuticals Ltd.Weight:
100 IU/mlbest Price:
৳ 550.00Generic
Protamine Crystallised Insulin Aspart
Pharmacology
Insulin Aspart rDNA is a sterile, clear solution of Insulin Aspart human insulin analogue for subcutaneous injection/infusion or intravenous injection. This is a blood glucose lowering agent with an earlier onset of action. It produces a more rapid onset of action compared to soluble human insulin. Insulin Aspart is homologous with regular human insulin with the exception of a single substitution of the amino acid Proline by aspartic acid in position B28, and is produced by recombinant DNA technology.
Contraindications
Instructions to be given to the patient before injecting this Insulin: According to the instruction given with ConviPen, insert the cartridge into the pen correctly & equip the needle Gently turn the pen upside down for 8-10 times until the insulin in the cartridge becomes uniformly mixed suspension Remove the needle cap, discharge air bubbles in the catridge Adjust the dosage button to get correct dose & inject to the specific site In order to avoid cross contamination, do not let the needle touch anything during the process of preparation.
Pregnancy And Lactation
A number of drugs affect glucose metabolism and may require dose adjustment. The following substances may reduce the Insulin as well as Insulin Aspart requirements: Oral anti-diabetic products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, propoxyphene, pentoxifylline, salicylates and sulfonamide antibiotics. The following substances may increase the Insulin as well as Insulin Aspart requirements: Thiazides, glucocorticoids, thyroid hormones, beta-sympathomimetics, growth hormone and danazol. Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood glucose lowering effect of insulin.
Therapeutic
Dose adjustment and monitoring: Blood glucose should be monitored in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision
Storage Conditions
A specific overdose for insulin cannot be defined, however, hypoglycaemia may develop over sequential stages if too high doses relative to the patient’s requirement are administered. Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously. Glucose must also be given intravenously if the patient does not respond to glucagon within 10 to 15 minutes. Upon regaining consciousness administration of oral carbohydrate is recommended for the patient in order to prevent relapse.
Over The Counter Products
